Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.07 AUD | +0.20% | -1.37% | +49.50% |
Sales 2024 * | 741M 492M | Sales 2025 * | 937M 623M | Capitalization | 4.97B 3.3B |
---|---|---|---|---|---|
Net income 2024 * | 48M 31.9M | Net income 2025 * | 103M 68.44M | EV / Sales 2024 * | 6.54 x |
Net cash position 2024 * | 128M 84.91M | Net cash position 2025 * | 195M 130M | EV / Sales 2025 * | 5.1 x |
P/E ratio 2024 * |
99.6
x | P/E ratio 2025 * |
47.8
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.41% |
Latest transcript on Telix Pharmaceuticals Limited
1 day | +0.33% | ||
1 week | -1.24% | ||
Current month | +0.27% | ||
1 month | +16.89% | ||
3 months | +36.44% | ||
6 months | +63.49% | ||
Current year | +49.70% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Kluge
FOU | Founder | - | 15-10-31 |
Founder | - | 15-10-31 | |
Darren Smith
DFI | Director of Finance/CFO | 58 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harry McCann
CHM | Chairman | 83 | 17-09-16 |
Founder | - | 15-10-31 | |
Mark Nelson
BRD | Director/Board Member | - | 17-09-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.39% | 14 M€ | -3.61% | ||
0.04% | 746 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 15.07 | +0.20% | 471 345 |
24-05-14 | 15.04 | -2.21% | 585,294 |
24-05-13 | 15.38 | -0.71% | 726,233 |
24-05-10 | 15.49 | +0.91% | 643,609 |
24-05-09 | 15.35 | +0.46% | 935,930 |
Delayed Quote Australian S.E., May 15, 2024 at 01:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.70% | 3.29B | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+43.45% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- TLX Stock